MedTrace Logo

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

NCT00407147 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-01-18

No results posted yet for this study

Summary

The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA) approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for antibiotic therapy in ICU patients with suspected infections.

Conditions

Interventions

DEVICE

Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor

antibiotic treatment based on clinical decision making with "traditional thought processes" used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.

Sponsors & Collaborators

  • Brahms AG

    lead INDUSTRY

Principal Investigators

  • Phil Dellinger, M.D. · The Cooper Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407147 on ClinicalTrials.gov